Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'

As Amarin expects jump in Vascepa sales from potential label expansion allowing larger patient group, John Thero notes competitors fail to show broader cardiovascular risk reduction, but consumers still hear omega-3 supplements "might work."